Skip to content
DataLookout
Menu

NCT05691491

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 65 versions: 15 with changes below, 35 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria revised
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 3 of 4 entries
    • Site details revised at 23 of 23 sites
  2. Minor Study sites revised (23)v64
  3. Minor Site details revised at 6 of 23 sitesv63
  4. Minor Enrollment reduced: 58 → 42 participants
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study description expanded, about 3 words
    v61
  5. Minor Study sites: 21 to 23v32
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Site details revised at 1 of 21 sitesv31
  2. Minor Study sites: 20 to 21v28
  3. Minor Study sites: 19 to 20v27
  4. Minor Site details revised at 1 of 19 sitesv26
  5. Minor Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)…v25
  6. Notable Primary and study completion dates: Jan 31, 2025 to Mar 1, 2027v24
  7. Minor Study sites: 13 to 19v20
  8. Minor Site details revised at 8 of 13 sitesv18
  9. Minor Site details revised at 7 of 13 sitesv17
  10. Minor Site details revised at 1 of 13 sitesv16
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose limiting toxicity and the maximum tolerated dose
Timeframe: Up to 28 days

Secondary (4)

Objective response rate (ORR)
Progression free survival (PFS)
Overall survival (OS)
Rate of >= grade 3 adverse events (AE)

Arms and interventions

Treatment (tuvusertib, temozolomide)Experimental

Patients receive tuvusertib PO QD) on days 1-7 and temozolomide PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI as well as collection of blood samples throughout the trial. Patients also undergo a biopsy at baseline and may undergo one on study and/or at time of progression.

Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging

Drugs: Temozolomide, Tuvusertib

Sites

23 sites in 1 country